{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:34:36Z","timestamp":1747172076488,"version":"3.40.5"},"reference-count":67,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.urolonc.2024.05.015","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T11:50:39Z","timestamp":1721217039000},"page":"372.e1-372.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biomarkers associated with survival in patients with platinum-refractory urothelial carcinoma treated with paclitaxel"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7654-4889","authenticated-orcid":false,"given":"Francesca","family":"Jackson-Spence","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Toms","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agne","family":"Jovaisaite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Protheroe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Birtle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabir","family":"Chakraborti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Huddart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santinder","family":"Jagdev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Bahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santhanam","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Crabb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernadett","family":"Szabados","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2024.05.015_bib0001","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0002","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up \u2606","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0003","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/14737140.2022.2028621","article-title":"Avelumab in locally advanced or metastatic urothelial carcinoma","volume":"22","author":"Jackson-Spence","year":"2022","journal-title":"Expert Rev Anticanc"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0004","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2217\/fon-2021-0841","article-title":"Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis","volume":"18","author":"Rizzo","year":"2022","journal-title":"Futur. Oncol."},{"key":"10.1016\/j.urolonc.2024.05.015_bib0005","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00262-022-03349-4","article-title":"Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis","volume":"72","author":"Santoni","year":"2023","journal-title":"Cancer Immunol., Immunother"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0006","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1200\/JCO.2008.20.5534","article-title":"Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract","volume":"27","author":"Bellmunt","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0007","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.eururo.2017.08.022","article-title":"Response rate to chemotherapy after immune checkpoint inhibition in metastatic urothelial cancer","volume":"73","author":"Szabados","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0008","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0009","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0010","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS498","article-title":"TROPiCS-04: Study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy","volume":"39","author":"Grivas","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0011","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0012","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.70.7828","article-title":"Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer","volume":"35","author":"Jones","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0013","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.eururo.2015.07.042","article-title":"Single-agent Taxane Versus Taxane-containing combination chemotherapy as salvage therapy for advanced urothelial carcinoma","volume":"69","author":"Sonpavde","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0014","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/annonc\/mdv509","article-title":"Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis","volume":"27","author":"Raggi","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The Hallmarks of Cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0016","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The Next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0017","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","author":"McLendon","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0018","doi-asserted-by":"crossref","first-page":"djt335","DOI":"10.1093\/jnci\/djt335","article-title":"Identification and validation of an anthracycline\/cyclophosphamide\u2013based chemotherapy response assay in breast cancer","volume":"106","author":"Mulligan","year":"2014","journal-title":"Jnci J National Cancer Inst"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0019","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms4361","article-title":"Genome-wide transcriptome profiling of homologous recombination DNA repair","volume":"5","author":"Peng","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0020","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1200\/JCO.2009.27.5719","article-title":"Gene expression profile of brcaness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer","volume":"28","author":"Konstantinopoulos","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0021","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13058-017-0861-2","article-title":"The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting","volume":"19","author":"Severson","year":"2017","journal-title":"Breast Cancer Res Bcr"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djw199","article-title":"Activation of STING-dependent innate immune signaling by S-PHASE-SPECIFIC DNA DAMAGE IN BREAST CANCER","volume":"109","author":"Parkes","year":"2017","journal-title":"Jnci J National Cancer Inst"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0023","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41540-017-0011-6","article-title":"Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm","volume":"3","author":"McGrail","year":"2017","journal-title":"Npj Syst Biology Appl"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0024","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/ng1861","article-title":"A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers","volume":"38","author":"Carter","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0025","doi-asserted-by":"crossref","first-page":"e56707","DOI":"10.1371\/journal.pone.0056707","article-title":"The CIN4 chromosomal instability qpcr classifier defines tumor aneuploidy and stratifies outcome in grade 2 breast cancer","volume":"8","author":"Sz\u00e1sz","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0026","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/jnci\/djs177","article-title":"A DNA repair pathway\u2013focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy","volume":"104","author":"Kang","year":"2012","journal-title":"Jnci J National Cancer Inst"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0027","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/sj.bjc.6602621","article-title":"Gene expression signatures for colorectal cancer microsatellite status and HNPCC","volume":"92","author":"Kruh\u00f8ffer","year":"2005","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0028","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0029","first-page":"137","article-title":"A signature-based method for indexing cell cycle phase distribution from microarray profiles","volume":"10","author":"Mizuno","year":"2009","journal-title":"Bmc Genomics [Electronic Resource]"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0030","doi-asserted-by":"crossref","first-page":"8330","DOI":"10.1038\/s41598-018-26613-z","article-title":"E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based treatments","volume":"8","author":"Lan","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0031","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.15252\/emmm.201607084","article-title":"CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib","volume":"9","author":"Rasp\u00e9","year":"2017","journal-title":"Embo Mol Med"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0032","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-19-0404","article-title":"Novel RB1-loss transcriptomic signature is associated with poor clinical outcomes across cancer types","volume":"25","author":"Chen","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0033","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1158\/1535-7163.MCT-09-1163","article-title":"Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor pha-793887 in tumor and skin biopsies from a phase i clinical study","volume":"9","author":"Locatelli","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2018.03.076","article-title":"Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas","volume":"23","author":"Knijnenburg","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0035","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1158\/1078-0432.CCR-14-3135","article-title":"Gene expression signatures predictive of bevacizumab\/erlotinib therapeutic benefit in advanced nonsquamous non\u2013small cell lung cancer patients (SAKK 19\/05 trial)","volume":"21","author":"Franzini","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0036","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1172\/JCI23412","article-title":"Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer","volume":"115","author":"Glinsky","year":"2005","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.urolonc.2024.05.015_bib0037","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/sj.onc.1208242","article-title":"Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer","volume":"24","author":"Hu","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0038","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/mc.20874","article-title":"Microarray meta-analysis defines global angiogenesis-related gene expression signatures in human carcinomas","volume":"52","author":"Anders","year":"2013","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0039","doi-asserted-by":"crossref","first-page":"10634","DOI":"10.18632\/oncotarget.3521","article-title":"Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer","volume":"6","author":"Stefansson","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0040","doi-asserted-by":"crossref","first-page":"e30269","DOI":"10.1371\/journal.pone.0030269","article-title":"Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer","volume":"7","author":"Bentink","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0041","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1200\/jco.2014.32.15_suppl.5502","article-title":"Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab","volume":"32","author":"Gourley","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0042","doi-asserted-by":"crossref","first-page":"24217","DOI":"10.18632\/oncotarget.8128","article-title":"Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel","volume":"7","author":"Mendiola","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0043","doi-asserted-by":"crossref","unstructured":"Hanahan, D. & Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0044","doi-asserted-by":"crossref","unstructured":"Hanahan, D. & Weinberg, R.A. The hallmarks of cancer. Cell 100, 57\u201370 (2000).","DOI":"10.1016\/S0092-8674(00)81683-9"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0046","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrm2858","article-title":"Genomic instability \u2014 an evolving hallmark of cancer","volume":"11","author":"Negrini","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0047","article-title":"Current insights into the regulation of programmed cell death by TP53 mutation in cancer","volume":"12","author":"Su","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0048","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41585-020-0304-1","article-title":"Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes","volume":"17","author":"Meeks","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0049","doi-asserted-by":"crossref","first-page":"805","DOI":"10.20892\/j.issn.2095-3941.2020.0177","article-title":"Evolving insights: how DNA repair pathways impact cancer evolution","volume":"17","author":"Zhou","year":"2020","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.urolonc.2024.05.015_bib0050","doi-asserted-by":"crossref","first-page":"6047","DOI":"10.1038\/s41598-021-84787-5","article-title":"Pancancer survival analysis of cancer hallmark genes","volume":"11","author":"Nagy","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0051","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3390\/cancers12051172","article-title":"Inducing angiogenesis, a key step in cancer vascularization, and treatment approaches","volume":"12","author":"Saman","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0052","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12865-018-0285-5","article-title":"Correlate tumor mutation burden with immune signatures in human cancers","volume":"20","author":"Wang","year":"2019","journal-title":"Bmc Immunol"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0053","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1634\/theoncologist.2019-0244","article-title":"Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence","volume":"25","author":"Klempner","year":"2020","journal-title":"Oncol"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0054","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.21037\/tau.2017.09.18","article-title":"Urology, Y. A. U. U. C. G. of the E. A. of. Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?","volume":"6","author":"Wezel","year":"2017","journal-title":"Transl Androl Urology"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0055","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41467-022-29441-y","article-title":"Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial","volume":"13","author":"Heijden","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0056","first-page":"1629","article-title":"Expression of class III beta-tubulin predicts prognosis in patients with cisplatin-resistant bladder cancer receiving paclitaxel-based second-line chemotherapy","volume":"38","author":"Miyata","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0057","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.7150\/ijms.59177","article-title":"Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer","volume":"18","author":"Chou","year":"2021","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0058","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230313","article-title":"A 3-gene biomarker signature to predict response to taxane-based neoadjuvant chemotherapy in breast cancer","volume":"15","author":"Kallarackal","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0059","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3109\/07357907.2012.725441","article-title":"Predictive biomarkers in breast cancer: their value in neoadjuvant chemotherapy","volume":"30","author":"Fuksa","year":"2012","journal-title":"Cancer Invest"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0060","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ygyno.2020.01.006","article-title":"Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients","volume":"156","author":"Fekete","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0061","doi-asserted-by":"crossref","DOI":"10.1177\/1179299X19860815","article-title":"Chemotherapy resistance in advanced ovarian cancer patients","volume":"11","author":"Pokhriyal","year":"2019","journal-title":"Biomarkers Cancer"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0062","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s00345-018-2544-8","article-title":"Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: are we understanding how, who and when?","volume":"37","author":"Schardt","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0063","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0064","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Kl\u00fcmper","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0065","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0066","doi-asserted-by":"crossref","first-page":"S721","DOI":"10.1016\/j.annonc.2021.08.112","volume":"32","author":"Powles","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2024.05.015_bib0067","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2217\/fon-2022-0868","article-title":"IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery","volume":"19","author":"Jackson-Spence","year":"2023","journal-title":"Futur. Oncol."}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924004915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924004915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T10:48:41Z","timestamp":1725360521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924004915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":67,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1078143924004915"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.05.015","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers associated with survival in patients with platinum-refractory urothelial carcinoma treated with paclitaxel","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}